Placeholder Banner

BIO Welcomes U.S. Involvement in COVAX, ACT Accelerator Programs

January 21, 2021
Media Contact

The Biden administration just announced its intent for the United States to join the COVAX vaccine facility, which aims to deliver COVID-19 vaccines to poor and under-developed countries.

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the following statement:

“As the organization representing U.S. biotechnology companies who are leading the world in the of development COVID vaccines and therapeutics, BIO welcomes Dr. Anthony Fauci’s statement today that the United States will be joining the global COVAX and ACT Accelerator programs, which are the chief international efforts charged with getting COVID treatments to patients around the world. 

“Medical breakthroughs in COVID can only fulfill their potential, and the global pandemic can only be effectively addressed if patients around the world get access to them. As the country developing more COVID vaccines and therapeutics than any other, it is appropriate and necessary that the United States also play a leadership role working with other countries and international organizations to make sure patients around the world receive them. 

“BIO looks forward to working with the U.S. and other governments to achieve this critical goal.”


Discover More
BIO to assess successes and challenges at its Digital Convention in June
Event Highlighted Leadership in Vaccine Development and Regional Growth in Biotechnology Innovation Gaithersburg, MD (September 24, 2020) – Today, Maryland Governor Larry Hogan and Dr. Michelle McMurry-Heath, President & CEO of Biotechnology…
As America’s researchers race to develop the scientific solutions needed to eradicate Covid-19, leaders within the Biotechnology Innovation Organization (BIO) released an open letter to their biopharmaceutical colleagues that articulates key…